Moving Toward Virtual Networks: Spotlight On Pfizer R&D
This article was originally published in PharmAsia News
PERTH, Australia - Pfizer's Asia strategy will focus on building a virtual network of collaborations with leading contract research organizations and academic groups rather than building bricks-and-mortar R&D facilities
You may also be interested in...
With AU$9.2 million in Series B financing, Australian drug delivery company prepares Phase II trial for levofloxacin antibiotic delivery system.
Pfizer is spinning off some of its Nagoya, Japan, research site into a venture-backed start-up called RaQualia Pharma Inc., the company reported July 3
Big Pharma Stretches To Reshape Itself To Enter Asia With Flexible, Multiple-Partner Networks – Singapore Conference
SINGAPORE - As big pharma looks across Asia for new ways of doing business, execs from the top pharma companies agreed that having people on the ground in Asia is critical and that companies are moving away from being fully integrated pharma companies to becoming fully integrated pharma networks